Nexus Pharmaceuticals announced the launch of Emerphed™, a premixed, ready-to-use formulation of ephedrine.
Emerphed is a sympathomimetic amine indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. The product is supplied as 50mg of ephedrine sulfate (equivalent to 38mg of ephedrine base) in 10mL single-dose vials (5mg/mL). The premixed formulation must not be diluted prior to administration.
Ephedrine sulfate works by directly acting as an alpha- and beta-adrenergic agonist and indirectly causing the release of norepinephrine. Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Ephedrine sulfate stimulates heart rate and cardiac output and variably increases peripheral resistance, resulting in increased blood pressure.
The efficacy of Emerphed is based on previously published literature. Blood pressure increases following administration of ephedrine were observed in 14 studies, including studies where ephedrine was used in pregnant women undergoing neuraxial anesthesia during Cesarean delivery, as well as in patients undergoing surgery under general anesthesia. The most common adverse reactions observed during treatment include nausea, vomiting, and tachycardia.
“We are proud to now have Emerphed available in the market, so that we can supply hospital institutions with the life-saving critical injectables that they have been asking for,” said Mariam S. Darsot, CEO & President of Nexus Pharmaceuticals.
For more information visit nexuspharma.net.